Herbert Newton, MD
-
Specialty: Hematology and Oncology
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English
Office Locations
UH Cleveland Medical Center (0 mi.)
11100 Euclid Ave
1st Floor
Cleveland, OH 44106
216-844-3951
Biography: Herbert Newton, MD
Expertise
Titles
- Medical Director, Brain Tumor Center, UH Seidman Cancer Center
- Director, Neuro-Oncology, UH Cleveland Medical Center
Certifications & Memberships
- Neurology - American Board of Psychiatry and Neurology
- Neuro-Oncology – United Council of Neurological Specialies
Education
Fellowship | Neuro-oncology
Neuro-oncology - Memorial Sloan-Kettering Cancer Center (1988 - 1990)
Residency | Neurology
Neurology - University Of Michigan Medical Center/University Of Michigan Health System (1985 - 1988)
Internship | Internal Medicine
Internal Medicine - Erie County Medical Center (1984 - 1985)
Medical Education
University At Buffalo Suny Jacobs School Of Medicine And Biomedical Sciences (1984)
Professional Education
University At Buffalo (1980)
Undergraduate
University At Buffalo (1979)
About
Herbert Newton, MD, FAAN, is a neuro-oncologist and Medical Director of the Brain Tumor Center at University Hospitals Seidman Cancer Center. Dr. Newton graduated from SUNY Buffalo with high honors in psychology, before pursuing a master’s degree in cancer chemotherapy and pharmacology from the Roswell Park Cancer Institute. He then entered the SUNY Buffalo School of Medicine, graduating in 1984. After an internship in internal medicine with the SUNY Buffalo Health System, he was trained in neurology at the University of Michigan Medical Center in Ann Arbor, MI, followed by a fellowship in neuro-oncology at the Memorial Sloan-Kettering Cancer Center (MSKCC) in New York City.
After the completion of his fellowship at MSKCC, Dr. Newton joined the faculty in Neurology at The Ohio State University Medical Center (OSUMC) and James Cancer Hospital, establishing a Division of Neuro-Oncology within the Department of Neurology. Dr. Newton achieved the rank of Full Professor of Neurology with tenure and was appointed the Esther Dardinger Endowed Chair in Neuro-Oncology in 2003.
His interests include clinical neuro-oncology, chemotherapy, molecular biology, molecular therapeutics, and clinical trials. After retiring from OSUMC in 2015, he then became the Director of the Neuro-Oncology Center for the Advent Health Cancer Institute and Advent Health Orlando campus, before returning to Ohio and UH in 2023. He has published more than 220 scientific articles and book chapters, and is the editor or co-editor of 12 books in the fields of neurology and neuro-oncology.
Research & Publications
Research Interests
Neuro-Oncology overall, but focusing on brain tumors; mainly high-grade gliomas and GBM, oligodendrogliomas, meningiomas, etc; chemotherapy, molecular therapeutics, clinical trials, NF-1 and NF-2, brain tumor-related epilepsy, brain metastases, leptomeningeal disease.
Featured Videos
Watch to find out more about this University Hospitals provider.
Patient Experience Reviews
Very kind man. Does not dismiss our concerns or opinions.
Dr Newton and Staff are excellent!
Dr. Newton and his team are great and that goes for all of our team of Surgeon, Radiation Oncologist and their teams ***
I appreciate the professionalism of the practice. Very knowledgeable and caring sf patients.
This cancer center has been very good to me
I love the staff at the entire hospital. My surgeon Dr. ***, as well as my current Dr Newton are wonderful!! *** and *** are great too.
I thought Dr Newton was very thorough.
Dr.Newton is great! *** He took time to discuss with me when I might be able to dive again and what healing needs to be complete before I ease back in. So glad *** referred me to him!
First appointment with Dr. Newton
Our first time with Dr Newton. We were very pleased. He's very nice and attentive.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Herbert Newton did not disclose any Outside Relationships with Industry.